Enterprise Value

-41.65M

Cash

118.7M

Avg Qtr Burn

-11.98M

Short % of Float

0.34%

Insider Ownership

41.27%

Institutional Own.

43.81%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

NDA

Submission

Phase 2b

Update

Phase 2

Update

Phase 1

Update

Failed

Discontinued

Rademikibart (CBP-201) (Th2 cell modulator) Details
Chronic rhinosinusitis, Chronic rhinosinusitis with nasal polyps

Failed

Discontinued